Episode 52: ASA Accreditation
Zoltan Harsanyi, Janet McDougall, and Theresa Utlaut discuss the PStat® and GStat® accreditations.

Zoltan Harsanyi, Janet McDougall, and Theresa Utlaut discuss the PStat® and GStat® accreditations.
Alexander Schacht and Benjamin Piske discuss their new podcast and the many ways statisticians can make themselves more effective.
ASA President Lisa LaVange describes her varied career across industry, government and academia, and discusses the establishment of the ASA Leadership Institute.
Heather discusses her goals for the Biopharmaceutical Section in 2018 and describes the life of a medical product statistician living in a non-traditional area.
Stephen Bamford, Chris Hurley and James Johnson discuss the motivation for and initiatives of PhUSE
Susan Wang and Amy Xia discuss the challenges of pediatric medical product development.
Gheorghe Doros, Anastasia Ivanova, and George Papakostas discuss the Sequential Parallel Comparison Design and the newly-formed Clinical Trial Designs with Re-Randomization of Subjects Scientific Working Group.
Kelly shares her thoughts on real world data and real world evidence in the healthcare and pharmaceutical industry.
Weili and Martin discuss the 2017 Regulatory-Industry Statistics Workshop.
Andy Grieve, Nigel Howitt, John Lewis and Lucy Rowell reminisce about PSI’s past and look forward to its future.
Reneé Moore and Janelle Charles discuss the mission and major initiatives of the Committee on Minorities in Statistics and the many ways statisticians can get involved.
Liz discusses the Health Policy Statistics Section (HPSS) of the ASA, the upcoming 2018 International Conference on Health Policy Statistics (ICHPS), as well as some of the major topic areas of focus for health policy statistics.
Yuki Ando, Frank Bretz, Rob Hemmings and Tom Permutt discuss estimands and the ICH E9 revisions.
Alex discusses multiplicity, the FDA’s draft guidance on multiple endpoints, and the BIOP pilot online training program.
Amanda discusses statistical leadership and her book Leadership and Women in Statistics.
Aloka Chakravarty, Laurie Letvak and Bill Wang discuss MRCTs and the draft ICH E17 guidance.
Sonia Davis, Bill Sollecito and Paula Brown Stafford discuss statistical leadership and leadership training at the University of North Carolina at Chapel Hill.
Alexander Schacht and Ian Hirsch discuss benefit-risk and the efforts of the EFSPI working group.
Telba Irony and Martin Ho discuss the important of patient preferences.
Freda and Ed discuss what to expect at the 2016 Biopharm Workshop
Marisa Bacchi discusses the first EFSPI workshop on regulatory statistics.
Marie Davidian, Montse Fuentes & Mladen Vouk define data science, discuss related ASA initiatives and describe the data science program at NC State.
Donna LaLonde, Dalene Stangl & Jiayang Sun discuss the origins and program for the upcoming WSDS conference.
Alan Hartford and Matt Rotelli discuss the mission of the group and the importance of communication between statisticians and pharmacometricians.
Nancy Flournoy, Ji-Hyun Lee, Paula Roberson and Jiayang Sun discuss the goals and activities of the caucus.
Veronica discusses the Center for Veterinary Medicine at FDA.
Michael Hale, Jonathan Hartzel, Sara Hughes, Ted Lystig & Estelle Russek-Cohen discuss the implications of data transparency for the pharmaceutical industry.
Greg Campbell discusses his career at the FDA and shares his thoughts on the future of medical product development.
Amit Bhattacharyya, Jie Chen, Frank Fan & Yang Song discuss the mission of the ISBS and the regulatory environment in China.
Wei and Richard discuss the 2015 ASA Biopharmaceutical Section Statistics Workshop. Rima Izem conducts the interview.